Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis

Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis Key PointsQuestionWhat factors are associated with the development of conjunctivitis in patients treated with dupilumab for atopic dermatitis? FindingsIn this case series of 12 adults in whom conjunctivitis developed during dupilumab treatment for atopic dermatitis, 9 had severe atopic dermatitis at baseline. Severe conjunctivitis was seen only in patients with severe atopic dermatitis at baseline and in those with another atopic condition in addition to atopic dermatitis. MeaningBaseline atopic dermatitis severity and history of atopic conditions should be considered when stratifying the risk for conjunctivitis development secondary to dupilumab administration for patients with atopic dermatitis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis

Loading next page...
 
/lp/american-medical-association/risk-factors-for-dupilumab-associated-conjunctivitis-in-patients-with-ojs7832ybC
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2018.2690
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionWhat factors are associated with the development of conjunctivitis in patients treated with dupilumab for atopic dermatitis? FindingsIn this case series of 12 adults in whom conjunctivitis developed during dupilumab treatment for atopic dermatitis, 9 had severe atopic dermatitis at baseline. Severe conjunctivitis was seen only in patients with severe atopic dermatitis at baseline and in those with another atopic condition in addition to atopic dermatitis. MeaningBaseline atopic dermatitis severity and history of atopic conditions should be considered when stratifying the risk for conjunctivitis development secondary to dupilumab administration for patients with atopic dermatitis.

Journal

JAMA DermatologyAmerican Medical Association

Published: Oct 29, 2018

References